A stem cells' metabolome
By using a metabolomic approach, a group of researchers have described some key differences between stem cells and mature cells as well as metabolites associated with the transition between the two.
As stem cells mature they change to form all the different cells that our bodies use. Control of this process could give doctors the tools to meet the needs of many patients with terrible conditions, such as Parkinson’s disease and spinal injuries. By using a metabolomic approach, a group of researchers have described some key differences between stem cells and mature cells as well as metabolites associated with the transition between the two.
Published in the on-line edition of Nature Chemical Biology,1 the study used LC–MS to analyse the stem cells’ metabolome and found 60 previously unidentified metabolites associated with the cell progression. “The study reveals an astounding cellular strategy,” commented Oscar Yanes, one of the researchers. “The capacity of embryonic stem cells to generate a whole spectrum of cell types characteristic of different tissues is mirrored at the metabolic level.”
The team suggests that the stem cells’ metabolome allows them to react to in vivo oxidative processes such as inflammation. Supporting this theory, the researchers found that by chemically blocking the oxidative processes, they were able to prevent stem cells’ normal progress into mature heart and nerve cells. Conversely, when specific oxidized metabolites were introduced downstream into the culture, stem cell differentiation was promoted.
1O. Yanes, Nature Chemical Biology, on-line 2 May 2010.
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
